3 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow 1018 oligonucleotide: new trials by email Literature Review of 1018 oligonucleotide trials Research Report on 1018 oligonucleotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults VLA1601, CpG 1018®, 3M-052-AF - Zika, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 150 | 2024-03-25 | 2026-03-09 |
| Innate Immunity Stimulation Via TLR9 in Early AD CpG1018, Placebo - Mild Cognitive Impairment, Alzheimer Dementia | Phase 1 | Recruiting | NYU Langone Health | 18 | 2023-03-13 | 2026-01-07 |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults BG505 SOSIP.664 gp140, Placebo, 3M-052-AF - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2020-01-13 | 2025-09-02 |
| Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma Rituxan, 1018 ISS - Non-Hodgkin's Lymphoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 30 | 2004-07-01 | 2010-01-29 |
Alzheimer Disease (1) · Cognitive Dysfunction (1) · HIV Infections (1) · Lymphoma, Non-Hodgkin (1) · Zika Virus Infection (1)
Dana-Farber Cancer Institute (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Valneva Austria GmbH (1)
United States (4)
Arjun Masurkar, MD (1) · Arnold Freedman, MD (1) · M. Juliana McElrath (1) · Nadine Rouphael (1)